Dated biotech reporting.
BioNTech's supervisory board appointed Guido Oelkers, chief executive of Swedish Orphan Biovitrum since 2017, as the company's next CEO on August 3, 2026, with the transition complete by February 1, 2027 at the latest, per the company. He succeeds co-founder Ugur Sahin, and the chief medical…
Eli Lilly said in May 2026 that it will invest an additional $4.5 billion at two of its three Lebanon, Indiana sites, lifting Indiana capital commitments above $21 billion over six years, per the company's announcement. A December 2025 decision to spend more than $6 billion on an Alabama API…
A conference abstract is a preliminary disclosure, not a publication, and the evidence for treating it cautiously is quantitative: in a Journal of Clinical Oncology study of 74 phase III abstracts presented at the 2000 ASCO Annual Meeting, 74% had corresponding journal publications six years…
Halozyme Therapeutics and Incyte entered a global collaboration and license agreement on July 20, 2026, granting Incyte rights to the ENHANZE drug delivery technology for subcutaneous formulations of INCA033989, per Halozyme's second-quarter report filed with the SEC. Incyte agreed to an upfront…
Johnson & Johnson reported second-quarter 2026 sales of $25.31 billion, up 6.6% year over year, with Innovative Medicine sales of $16.384 billion, up 7.8% — per the earnings release filed with the SEC on July 15, 2026. The company raised full-year guidance to reported sales of $101.1 billion and…
FDA's public comment window on its proposed Expedited IND pilot program closes July 22, 2026, per a Federal Register notice published June 24. The docket follows a stretch in which clinical holds hit three high-profile gene therapy programs, including both REGENXBIO MPS trials, per the company's…